This trial will test the safety and effectiveness of a new drug, GSK3745417, for treating cancer. The trial will have two parts, each testing different ways of administering the drug.
10 Primary · 32 Secondary · Reporting Duration: Up to 2 years
Side Effects for
2 Treatment Groups
Part 2A: Participants receiving GSK3745417 + dostarlimab, Dose escalation Cohort
1 of 2
Part 1A: Participants receiving GSK3745417, Dose-escalation Cohort
1 of 2
300 Total Participants · 2 Treatment Groups
Primary Treatment: GSK3745417 · No Placebo Group · Phase 1
Who is running the clinical trial?
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Are individuals currently being enrolled in this experiment?
"Confirmatively, this research is currently recruiting patients. The posting was first seen on March 12th 2019 and the last update was November 21st 2022." - Anonymous Online Contributor
Could you summarize any additional investigations that have been conducted surrounding GSK3745417?
"GSK3745417, which was initially examined in 2010 by City of Hope, has already seen 179 trials finished. Currently there are 40 more studies being conducted out of Houston, Texas." - Anonymous Online Contributor
What is the population volume of this research experiment?
"Affirmative. Information found on clinicaltrials.gov indicates that this medical trial is still recruiting participants; the study was first published in March 12th 2019 and recently amended on November 21st 2022. 300 patients need to be recruited at 3 distinct locations." - Anonymous Online Contributor
Has the Food and Drug Administration given its seal of approval to GSK3745417?
"As this trial is in its early stages, the safety of GSK3745417 was assigned a score 1. This means that while efficacy has been preliminarily established, there are limited data points verifying safety." - Anonymous Online Contributor